●Abstract Submission Period

February 3 (Mon), 2025 – November 28 (Fri), 2025

●Abstract Submission

Abstract submission is available on the online site only.

●SCPSC2026 accepts abstracts for free paper.

The presentation will be in the form of an oral or poster presentation.

●Guideline

We accept abstracts submitted online only through the submission system. You may enter the submission page from "Abstract Submission" button at the bottom of this page.

1.Author information and abstracts must be submitted in English.

2.The final decision on presentation style will be announced at the time of acceptance.
Please note that you may be assigned to present in Poster style even when you choose Oral style.

3.It is recommended that you prepare your abstract text by Word/ text file in advance, and then copy it on the registration page.

4.Abstract title must be up to 120 single-byte characters.

5.Abstract text must be up to 1,200 single-byte characters.

6.The maximum of 6 authors (first author & co-authors) can be registered.

7.Any chart or diagram cannot be included.

8.Special characters are not allowed.

●Please select the abstract category from the list below.

【Abstract Category】

1.Advance care planning

2.Artificial intelligence in palliative oncology

3.Assisted suicide and euthanasia

4.Biology of opioids in palliative cancer care
・Genome-wide association study of opioids
・Opioid system on the neuro-immune - endocrine function
・Pharmacology of opioid

5.Biology of symptoms and treatment toxicities

6.Caregiver support

7.Communication and shared decision making

8.End of life care

9.Mental health and psychological well-being

10.Palliative care as a human right

11.Palliative oncology
・Cancer immunology, immunotherapy and palliative care
・Palliative chemotherapy, radiotherapy and surgery
・Targeted therapy and CART-T cell therapy in palliative cancer care

12.Patient reported outcomes and patient experience

13.Pediatric palliative care and pediatric pain

14.Prevention, assessment, and management of disease and treatment-related symptoms

15.Prognostication

16.Psychoanalysis in palliative care

17.Public health strategy for palliative care

18.Rehabilitation in palliative cancer care

19.Spiritual suffering and existential suffering

20.Survivorship and late effects of cancer

21.Technology enabled care services

22.Other

●Disclosure of Conflict of Interest at the 5th SCPSC 2026

The presenter (the first author) and the principal investigator must disclose the name of any company or for-profit organization related to medicine they have a relationship with, defined as follows: in the following items (3) to (9), (11), (12), exceeding separately stipulated criteria, and (1), (2), (10), (13) if met. The subject period is from January 1, 2024 -December 31, 2024.
For poster presentation, please prepare and print out the slide, and put it at lower right of the poster panel.

(1) If your study for this presentation is supported by research funds

(2) If you are or have been an employee of a company and/or a profit-making organization related to medicine

(3) If you have earned ＞1,000,000 JPY/year as an officer or advisor of a company and/or a profit-making organization related to medicine

(4) If you hold＞5％ of the stock of a company and/or a profit-making organization related to medicine, or receive dividends ＞1,000,000 JPY/year

(5) If you have earned ＞1,000,000 JPY/year as a patent fee from a company and/or a profit-making organization related to medicine

(6) If you have earned ＞500,000 JPY/year as a lecture fee from a company and/or a profit-making organization related to medicine

(7) If you have earned ＞500,000 JPY/year as a manuscript fee from a company and/or a profit-making organization related to medicine

(8) If you have research expenses ＞1,000,000 JPY/year from a company and/or a profit-making organization related to medicine

(9) If you have received ＞1,000,000 JPY/year as a certain contribution from a company and/or a profit-making organization related to medicine

(10) If you are or have been involved in a certain endowed chair funded by a company and/or a profit-making organization related to medicine

(11) If you have ＞1,000,000 JPY/year as a fee for expert comment, judgment or testimony in legal proceedings, or others from a company and/or a profit-making organization related to medicine

(12) If you have received remuneration (travel, gifts, or other in-kind payments not directly related to research）equivalent to ＞50,000 JPY/year from a company and/or a profit-making organization related to medicine

(13) If you are a representative of an organization for clinical study which receives research expenses（donation, contract, others）from a company and/or a profit-making organization related to medicine

●Ethical principles for declaring ethical matters of your abstract

In order to review whether your abstract is conformed to the standard of applicable research ethics such as "GCP", "GPSP", "Ethical guidelines on medical research on humans", "Ethical guidelines on research on human genome and gene analysis", etc., SCPSC ask you to declare the following items:

□Does your study include medical research on human subjects, human material or human data?

□Does your study comply with the Declaration of Helsinki?

□Was your study approved by an institutional review board before starting the research?

●Email notification of acceptance/rejection

Notification of acceptance or rejection will be announced by email at the end of January, 2026 to the email address you registered when submitting your abstract.
The detailed information about presentation schedule, such as date and place, is going to be mentioned in the notification of acceptance.